Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645060 · ClinicalTrials.gov registry record · Phase 1
Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00645060 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00645060, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for advanced cancer. PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A in treating patients with advanced solid tumors.
Interventions
- OTHER pharmacological study
- PROCEDURE radionuclide imaging
- OTHER high performance liquid chromatography
- PROCEDURE single photon emission computed tomography
- RADIATION yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-10-09 |
| Est. Completion | 2016-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645060
The ClinicalTrials.gov registry entry for NCT00645060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00645060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645060 about?
NCT00645060 is a clinical study titled "Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors". RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for advanced cancer. PURPOSE: This phase I trial is studying th...
What is the current status of trial NCT00645060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-10-09. Estimated completion is 2016-09-06.
What interventions are being tested in trial NCT00645060?
The interventions under investigation include: pharmacological study (OTHER), radionuclide imaging (PROCEDURE), high performance liquid chromatography (OTHER), single photon emission computed tomography (PROCEDURE), yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A (RADIATION).
Who is sponsoring clinical trial NCT00645060?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.